PhaseBio Pharmaceuticals Executives
PhaseBio Pharmaceuticals employs about 60 people. The company is managed by 8 executives with a total tenure of roughly 140 years, averaging almost 17.0 years of service per executive, having 7.5 employees per reported executive. Discussion of PhaseBio Pharmaceuticals' management performance can provide insight into the enterprise performance.
| Jonathan MBA Insider CEO Pres |
| Susan Arnold Insider VP Operations |
PhaseBio |
PhaseBio Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (1.0607) % which means that it has lost $1.0607 on every $100 spent on assets. This is way below average. PhaseBio Pharmaceuticals' management efficiency ratios could be used to measure how well PhaseBio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.PhaseBio Pharmaceuticals owns a total of 49.86 Million outstanding shares. PhaseBio Pharmaceuticals holds 6.72 pct. of its outstanding shares held by insiders and 25.02 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
PhaseBio Pharmaceuticals Workforce Comparison
PhaseBio Pharmaceuticals is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 244. PhaseBio Pharmaceuticals totals roughly 60.0 in number of employees claiming about 25% of stocks in Biotechnology industry.
PhaseBio Pharmaceuticals Notable Stakeholders
A PhaseBio Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as PhaseBio Pharmaceuticals often face trade-offs trying to please all of them. PhaseBio Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting PhaseBio Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jonathan MBA | CEO Pres | Profile | |
| Susan Arnold | VP Operations | Profile | |
| Lawrence Perkins | Chief Officer | Profile | |
| Jonathan Birchall | Chief Officer | Profile | |
| Kristopher Hanson | Gen SVP | Profile | |
| Lauren Richardson | Global Assurance | Profile | |
| Glen Burkhardt | VP HR | Profile | |
| John CPA | Chief Officer | Profile |
PhaseBio Pharmaceuticals Workforce Analysis
Traditionally, organizations such as PhaseBio Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare PhaseBio Pharmaceuticals within its industry.PhaseBio Pharmaceuticals Manpower Efficiency
Return on PhaseBio Pharmaceuticals Manpower
| Revenue Per Employee | 180.5K | |
| Revenue Per Executive | 1.4M | |
| Net Loss Per Employee | 2.2M | |
| Net Loss Per Executive | 16.4M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |